<DOC>
	<DOCNO>NCT01262300</DOCNO>
	<brief_summary>This ancillary study randomize control trial high dose vitamin D old long-term care resident ( NCT01102374 ) . In study , subset trial subject receive zoster vaccine determine immunological response vaccine older , frail population , well association vitamin D immunological outcome .</brief_summary>
	<brief_title>Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents</brief_title>
	<detailed_description>Objectives 1 . To determine increase VZV-specific cell-mediated immune response pre-zoster vaccination 3 week post-vaccination nursing home resident 4 month high dose vs. standard dose vitamin D3 supplementation . 2 . In participant Aim 1 , measure association pre-zoster vaccination 25-hydroxyvitamin D [ 25 ( OH ) D ] level increase VZV-specific cell-mediated immune response pre- vaccination 3 week post-vaccination . 3 . Characterize phenotypic functional VZV-specific T cell response Zostavax , include memory , effector , Th1/Th2 , home receptor-bearing T cell high compare low ELISPOT responder . Hypotheses 1 . At baseline , high serum 25 ( OH ) D level associate high level VZV-specific cell-mediated immunity ( cross-sectional ) . 2 . At baseline , high serum 25 ( OH ) D level , independent vitamin D supplementation dose , associate great increase VZV-specific cell-mediated immune response Zostavax , measure interferon ( IFN ) -γ ELISPOT assay . 3 . Compared standard dose , high dose vitamin D3 supplementation enhance VZV-specific cell-mediated immune response vaccination independent baseline serum 25 ( OH ) D level .</detailed_description>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 ) Aged ≥ 60 year ; 2 ) Residing longterm care facility ; 3 ) Have yet receive VZV vaccine 1 ) terminal illness ( expect survival &lt; 6 month ) ; 2 ) anticipate discharge within 12 month ; 3 ) unable take whole crush tablet ; 4 ) active cancer , except squamous/basal cell carcinoma ; 5 ) severe malnutrition ( body mass index &lt; 18 kg/m2 ) ; 6 ) current immunosuppressive medication ( include corticosteroid ) ; 7 ) renal failure ( eGFR &lt; 15 mL/min/1.73m2 ) ; 8 ) currently take &gt; 800 IU/d vitamin D supplementation ; 9 ) history ( strong family history ) kidney stone ; 10 ) history sarcoidosis granulomatous disorder associate hypercalcemia ; 11 ) elevate baseline hypercalcemia ( albuminadjusted serum calcium &gt; 10.5 mg/dL ) ; 12 ) serum 25 ( OH ) D level ≥40 ngl/ml baseline ; 13 ) inability provide inform consent available healthcare proxy ; 14 ) inability participant proxy speak/understand English . 15 ) previous receipt Zostavax ( anticipate &lt; 10 % trial ; 16 ) know allergy gelatin , neomycin , component vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immunosenescence</keyword>
	<keyword>Shingles</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Varicella Zoster Virus</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immune Response</keyword>
	<keyword>Geriatrics</keyword>
</DOC>